| Filed On | Filing |
|---|---|
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa |
| 13 Oct 2026 |
Form 4: Musunuri Shankar, Director
Sold 525,991 shares ($500K) |
| 09 Oct 2026 | 144 |
| 06 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 5, 2026, Ocugen, Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”) virtually, which had been adjourned on September 21, 2026 solely with respect to the proposal to approve the adoption... |
| 23 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 21, 2026, Ocugen, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually, which was adjourned to October 5, 2026 solely with respect to the proposal to approve the adoption of an amendm... |
| 11 Sep 2026 |
Form 4: Musunuri Shankar, Director
Sold 525,991 shares ($589K) |
| 09 Sep 2026 | 144 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally |
| 14 Aug 2026 | DEFA14A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jul 2026 | DEFA 14A |
| 30 Jul 2026 | Proxy statement: special meeting on September 21, 2026 |
| 29 Jul 2026 | SCHEDULE 13G |
| 20 Jul 2026 | PRE 14A |
| 13 Jul 2026 | 8-K: Other Events |
| 17 Jun 2026 |
Form 4: Johnson-Greene Treerita Essalima, Chief Financial Officer
Bought 21,000 shares ($25.8K) |
Loading...
